Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $118.27 to $122.22
• 50-Day Range: $122.33 to $147.56
• 52-Week Range: $55.25 to $173.25
• Volume: 1.38 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $11.23 billion
• P/E Ratio: 1,079.64
• Dividend Yield: N/A
• Price Target: $187.39
• Consensus Rating: Moderate Buy

Sarepta Therapeutics Stock Analysis - MarketRank™

Sarepta Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 20th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sarepta Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 608.28%

Earnings Growth

Earnings for Sarepta Therapeutics are expected to grow by 608.28% in the coming year, from $1.45 to $10.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sarepta Therapeutics is 1,079.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 134.07.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sarepta Therapeutics is 1,079.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 140.60.

Price to Book Value per Share Ratio

Sarepta Therapeutics has a P/B Ratio of 12.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.51% of the outstanding shares of Sarepta Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Sarepta Therapeutics has recently decreased by 5.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sarepta Therapeutics does not currently pay a dividend.

Dividend Growth

Sarepta Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.65

Percentage of Shares Shorted

6.51% of the outstanding shares of Sarepta Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Sarepta Therapeutics has recently decreased by 5.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.76

News Sentiment

Sarepta Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.

Search Interest

Only 12 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Sarepta Therapeutics insiders have bought 502.81% more of their company's stock than they have sold. Specifically, they have bought $4,955,684.00 in company stock and sold $822,100.00 in company stock.

Percentage Held by Insiders

Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

Percentage Held by Institutions

86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRPT Stock Analysis - Frequently Asked Questions

How have SRPT shares performed this year?

Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT shares have increased by 23.2% and is now trading at $118.76.
View the best growth stocks for 2024 here.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Wednesday, August, 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The firm's revenue was up 38.9% on a year-over-year basis.

Does Sarepta Therapeutics have any subsidiaries?

Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 10/03/2024
• Next Earnings (Estimated): 11/06/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRPT
• Previous Symbol: NASDAQ:AVII
• CUSIP: N/A
• CIK: 873303
• Web: www.sareptatherapeutics.com
• Phone: (617) 274-4000
• Fax: 425-354-5038
• Employees: 1,314
• Year Founded: 1980

Price Target and Rating

• Average Stock Price Target: $187.39
• High Stock Price Target: $235.00
• Low Stock Price Target: $109.00
• Potential Upside/Downside: +56.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.95
• Research Coverage: 19 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.11
• Trailing P/E Ratio: 1,090.27
• Forward P/E Ratio: 82.71
• P/E Growth: N/A
• Net Income: $-535,980,000.00
• Net Margins: 3.14%
• Pretax Margin: 4.13%
• Return on Equity: 5.32%
• Return on Assets: 1.50%

Debt

• Debt-to-Equity Ratio: 1.05
• Current Ratio: 3.90
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $1.50 billion
• Price / Sales: 7.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.19 per share
• Price / Book: 13.05

Miscellaneous

• Outstanding Shares: 94,524,000
• Free Float: 87,246,000
• Market Cap: $11.34 billion
• Optionable: Optionable
• Beta: 0.81